ArticleMOJ lymphology & phlebology2017
Can Protein Restriction Set Up T Lymphocytes Favorably For Their Activation Against Pathogens Through Myc?
Article in MOJ lymphology & phlebology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
One area that presents a significant threat to global health is infectious diseases. With increasing prevalence of antibiotic-resistant bacteria [1], opportunistic infections are a growing concern for human societies. In 2009, there were 89,000 deaths caused by pneumonia, septicemia, and influenza virus in the United States alone [2]. Antibiotic-resistant bacteria increase the risk of secondary infection that is associated with many standard medical procedures such as organ transplantation, chemotherapy, dialysis, and elective surgery [1]. The deceleration of new drug discovery suggests that acute preventative strategies strengthening host immunity prior to such procedures are of strong interest. In this mini review, I will suggest a protein restriction-Myc signaling as a potential pharmacological target to boost the survival outcome following pathogenic bacterial infection.
Indexed as
Identifiers
29205230PMC5708585W2756040325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.